Yonsu Son

Hirakata, 5731191, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

Real-world comparison of herpes zoster risk among five Janus kinase inhibitors in rheumatoid arthritis: The ANSWER cohort study.

Real-world comparison of herpes zoster risk among five Janus kinase inhibitors in rheumatoid arthritis: The ANSWER cohort study.

Journal: Joint bone spine

Published: March 26, 2026

Clinical outcomes of molecular-targeted therapies for rheumatoid arthritis: comparison between orthopaedic surgeons and rheumatologists in the multicenter retrospective ANSWER cohort.

Clinical outcomes of molecular-targeted therapies for rheumatoid arthritis: comparison between orthopaedic surgeons and rheumatologists in the multicenter retrospective ANSWER cohort.

Journal: Clinical rheumatology

Published: February 12, 2026

Mode of action-specific and cause-specific retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in anti-SS-A antibody-positive rheumatoid arthritis: The ANSWER cohort study.

Mode of action-specific and cause-specific retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in anti-SS-A antibody-positive rheumatoid arthritis: The ANSWER cohort study.

Journal: PloS one

Published: December 01, 2025

Personalized exercise therapy during targeted drug therapy tapering in patients with rheumatoid arthritis: a pilot randomized controlled trial.

Personalized exercise therapy during targeted drug therapy tapering in patients with rheumatoid arthritis: a pilot randomized controlled trial.

Journal: BMC rheumatology

Published: October 30, 2025

Baseline neutrophil-to-lymphocyte ratio predicts drug retention of IL-6 inhibitors and JAK inhibitors in RA: the ANSWER cohort study.

Baseline neutrophil-to-lymphocyte ratio predicts drug retention of IL-6 inhibitors and JAK inhibitors in RA: the ANSWER cohort study.

Journal: Rheumatology (Oxford, England)

Published: August 01, 2025

Effect of treat-to-target strategies on maternal and neonatal outcomes of rheumatoid arthritis: a multicentre real-world ANSWER cohort study.

Effect of treat-to-target strategies on maternal and neonatal outcomes of rheumatoid arthritis: a multicentre real-world ANSWER cohort study.

Journal: Rheumatology (Oxford, England)

Published: June 17, 2025

Clinical efficacy of JAK inhibitors for RA patients with poor-prognosis factors: the ANSWER cohort study.

Clinical efficacy of JAK inhibitors for RA patients with poor-prognosis factors: the ANSWER cohort study.

Journal: Rheumatology (Oxford, England)

Published: April 22, 2025

Distinct impact of RF and ACPA titre on the effectiveness and persistency of biologics and JAK inhibitors: The ANSWER cohort study.

Distinct impact of RF and ACPA titre on the effectiveness and persistency of biologics and JAK inhibitors: The ANSWER cohort study.

Journal: Modern rheumatology

Published: January 17, 2025

Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study.

Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study.

Journal: Arthritis research & therapy

Published: December 15, 2024

Differential Impact of Concomitant Methotrexate and Glucocorticoids Dosages on Biologics and JAK Inhibitors: The ANSWER Cohort Study.

Differential Impact of Concomitant Methotrexate and Glucocorticoids Dosages on Biologics and JAK Inhibitors: The ANSWER Cohort Study.

Journal: International journal of rheumatic diseases

Published: November 28, 2024

Sustained efficacy of second-line JAK inhibitors in patients with rheumatoid arthritis: insights from the ANSWER cohort.

Sustained efficacy of second-line JAK inhibitors in patients with rheumatoid arthritis: insights from the ANSWER cohort.

Journal: Rheumatology (Oxford, England)

Published: November 15, 2024

Comparative effects of biological and targeted synthetic DMARDs on incident chronic kidney disease in patients with rheumatoid arthritis.

Comparative effects of biological and targeted synthetic DMARDs on incident chronic kidney disease in patients with rheumatoid arthritis.

Journal: Rheumatology (Oxford, England)

Published: July 01, 2024

Showing 1-12 of 50

Last Updated: 09/26/2026